Remdesivir from failed Ebola drug to first FDA-approved COVID-19 antiviral: The medico-legal integration.

Publication date: Aug 21, 2026

Remdesivir became the first antiviral for COVID-19 to receive emergency use authorization (EUA) and, subsequently, full FDA approval. This article provides a statutory analysis of its development life cycle, tracing the contributions of nine US federal statutes from foundational coronavirus science through full approval, using a qualitative regulatory-science method that combines doctrinal and document analysis. Each statute is mapped onto a staged life cycle framework. The National Institute of Allergy and Infectious Diseases, under 42 U. S.C. > 282, designed and ran the pivotal the adaptive COVID-19 treatment trial (ACTT-1), generating EUA-supporting evidence in 14 weeks; Biomedical Advanced Research and Development Authority’s (BARDA) Other Transaction Authority enabled at-risk manufacturing before the EUA; the Project BioShield Act addressed the market failure of an intravenous, hospital-only antiviral; and the Defense Production Act supported domestic supply. Together, these interdependent statutes show how an integrated legal architecture compressed development into months. Sustaining this institutional infrastructure is the most consequential investment in pandemic preparedness.

Open Access PDF

Concepts Keywords
Coronavirus disaster preparedness law
Ebola emergency use authorization
Fda pandemic medical countermeasures
Hospital PREP Act
Qualitative remdesivir

Semantics

Type Source Name
disease MESH COVID-19
disease MESH emergency
disease MESH Allergy
disease MESH Infectious Diseases
drug DRUGBANK Ranitidine
drug DRUGBANK Adenosine
disease MESH included
pathway REACTOME Release
disease MESH HHS
drug DRUGBANK Trestolone
drug DRUGBANK Valproic Acid
drug DRUGBANK Cysteamine
pathway KEGG Viral replication
disease MESH infection
disease MESH fed
disease MESH influenza
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Oxygen
drug DRUGBANK Etoperidone
drug DRUGBANK L-Phenylalanine
drug DRUGBANK Methionine
disease MESH Injury
disease MESH Plan
disease MESH hos
disease MESH tals
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Dexamethasone
disease MESH ces
drug DRUGBANK Ritonavir
disease MESH death
disease MESH anthrax
disease MESH STAR
drug DRUGBANK Spinosad
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Chloroquine
drug DRUGBANK Tretamine
disease MESH tic
drug DRUGBANK Coenzyme M
disease MESH AGs
disease MESH mul
disease MESH Dis

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *